AI helps drug development open up a new path that is both faster and more economical

Recently, at the "From 'AI+Medical' to Digital Healthcare: Opportunities and Challenges Forum", Kai-Fu Lee, Chairman and CEO of Sinovation Ventures, said: "In terms of medical innovation, a big bottleneck is that there are only so many people who are capable of inventing new drugs. He further elaborated: "The intervention of artificial intelligence (AI) is gradually breaking this shackles and opening up a new path of 'fast and economical' in the field of drug research and development. With its powerful data processing capabilities, deep learning algorithms and pattern recognition technology, AI can accelerate the analysis of massive amounts of bioinformatics data, including gene sequences, compound libraries, clinical trial results, etc., to discover potential drug targets and treatment plans. This process not only greatly shortens the time cycle required for traditional drug research and development from several years or even more than ten years to several months or years, but also significantly reduces research and development costs and reduces the failure rate in clinical trials. More importantly, AI can simulate complex biological interaction processes, predict the safety and effectiveness of drugs, and enable research and development. With the continuous maturity of technology and the continuous accumulation of data, AI will play an increasingly core role in the field of drug research and development, promote the advent of more innovative drugs, bring hope of life to patients, and also bring revolutionary changes to the medical industry. "